Welcome to our dedicated page for Lifeward SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lifeward Ltd. (Nasdaq: LFWD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Lifeward is a medical device company focused on rehabilitation technologies such as the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System, and it is incorporated in the State of Israel with ordinary shares listed on the Nasdaq Capital Market.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss Lifeward’s product portfolio, geographic operations in the United States, Israel, and Germany, reimbursement developments for personal exoskeletons, and risk factors relevant to its medical technology business. AI tools highlight key sections, such as discussions of CMS reimbursement pathways, international sales, and operational initiatives.
Lifeward’s current reports on Form 8-K are especially important for tracking material events. Recent 8-K filings describe a Nasdaq bid-price deficiency notice, a secured promissory note and loan agreement with Oramed Ltd., preliminary financial results, the appointment of a new Chief Financial Officer, the approval of a 2025 Incentive Compensation Plan, and the results of the 2025 annual shareholder meeting. AI summaries surface the main terms of these events, including financing structures, compliance timelines, and governance changes.
Investors can also monitor registration statements such as the Form S-1 and S-1/A related to offerings of ordinary shares and warrants. These documents outline Lifeward’s status as a smaller reporting company, describe the securities being offered, and provide additional detail on use of proceeds and capital structure. Where applicable, the platform also surfaces insider transaction reports on Form 4 to show equity awards or share dealings by directors and officers, if and when such filings are made.
All filings are sourced in real time from the SEC’s EDGAR system. AI-powered analysis helps explain technical language, highlight covenant and dilution terms in financing agreements, and point out items that may affect shareholders of LFWD, without replacing a careful reading of the original documents.
Lifeward Ltd. reports its 2025 annual business overview as a specialized neurorehabilitation and mobility medical device company. The company sells ReWalk powered exoskeletons for spinal cord injury, ReStore soft exo-suits for stroke rehab, and AlterG Anti-Gravity systems used in over 6,000 facilities globally.
Lifeward highlights U.S. and European reimbursement progress, including Medicare’s brace benefit classification for personal exoskeletons and a final DMEPOS fee schedule amount of $91,032 per device under HCPCS code K1007. Veterans Health Administration policies and German statutory insurer contracts continue to support case-by-case coverage.
Strategically, Lifeward agreed to acquire Oratech Pharma from Oramed in a share and warrant deal that will give Oramed up to 49.99% of Lifeward’s fully diluted equity and 4% revenue sharing on ReWalk products, alongside up to $20.0 million of senior secured convertible notes and high-interest bridge loans. Additional moves include a Skelable IP acquisition for upper-limb robotics and new distribution agreements with CorLife for U.S. workers’ compensation and Verita Neuro for select international markets.
Lifeward Ltd. reported fourth quarter and full-year 2025 results while advancing a major strategic shift toward diversified biomedical innovation. Full-year 2025 revenue was $22.0 million, down from $25.7 million in 2024, but GAAP net loss narrowed to $19.9 million from $28.9 million as operating expenses fell 25%.
Fourth-quarter 2025 revenue was $5.1 million versus $7.5 million a year earlier, with lower AlterG and MyoCycle sales partly offset by stronger ReWalk exoskeleton revenue. Lifeward secured shareholder approval for a transformative Oramed transaction, under which Oramed may own up to 49.99% of Lifeward and provide up to $47 million in funding while contributing its POD™ oral protein delivery platform. The company also agreed to acquire a powered upper-body exoskeleton, targeting commercial launch in roughly 18–24 months. Cash and cash equivalents were $2.2 million as of December 31, 2025.
Lifeward Ltd. reported the results of its extraordinary shareholder meeting held on March 12, 2026. Shareholders representing 7,252,783 ordinary shares, about 39.7% of the 18,293,776 shares outstanding as of January 20, 2026, were present or voted, forming a quorum.
Investors approved issuing ordinary shares to Oramed Pharmaceuticals Inc. for the acquisition of 100% of Oratech Pharma, Inc., and related warrants and convertible note issuances tied to that deal. They also approved electing two external directors effective at the Oratech closing, their compensation framework, increasing shares under the 2025 Incentive Compensation Plan, and an equity grant to CEO Mark Grant.
Shareholders further approved reappointing Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent auditor for the year ending December 31, 2026, with the board authorized to set its remuneration.
Lifeward Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price listing standard. The company received written notice from Nasdaq’s Listing Qualifications Hearings Department confirming that its Ordinary Shares met the $1.00 per share minimum closing bid price for 10 consecutive business days from February 24, 2026 to March 9, 2026. Nasdaq stated that the minimum bid price matter is now closed, meaning Lifeward’s Ordinary Shares continue to qualify for listing on the Nasdaq Capital Market.
Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares effective February 24, 2026. The move is intended to help the company meet the $1.00 minimum bid price required to keep its Nasdaq Capital Market listing.
The reverse split reduced issued and outstanding ordinary shares from 18,339,098 to approximately 1,528,098, while the company’s authorized ordinary shares increased from 75,000,000 to 100,000,000 under its Eighth Amended and Restated Articles of Association. No fractional shares were issued, with holdings rounded down to the nearest whole share, and the shares now trade on a split-adjusted basis under the existing symbol LFWD.
Lifeward Ltd. reported a change in its Board of Directors. On February 24, 2026, Class I director Hadar Levy notified the Board of his decision to step down, effective the same day. The company stated that his departure was not due to any disagreement regarding operations, policies or practices, and expressed gratitude for his service and contributions.
Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Skelable Ltd. on February 19, 2026. Lifeward will acquire specified intellectual property and related technology assets and bring certain key Skelable employees on board under new employment agreements.
As consideration, Lifeward will pay up to $500,000 in three milestone-based installments, with $480,000 payable in ordinary shares and $20,000 in cash. The shares will be priced at the higher of the prior trading day’s closing price or the daily volume-weighted average price. These shares will be issued as an unregistered offering relying on the Section 4(a)(2) exemption under the Securities Act of 1933. The initial closing of the transaction is expected to occur in the near future, subject to customary conditions.
Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for an initial principal amount of $525,000, which may be increased by up to an additional $975,000 upon mutual consent. This follows a prior secured promissory note for $3.0 million that remains outstanding.
The new note is secured by a lien on the company’s cash, carries interest at 24% per annum, and matures on the earlier of August 12, 2026 or the company’s failure to obtain shareholder approval for the transactions under the January 12, 2026 securities purchase and share purchase agreements. It includes customary covenants restricting additional indebtedness, liens, major transactions, and affiliate dealings, and defines standard events of default such as non-payment, covenant breaches, insolvency, and material adverse effects.
Upon default, Oramed may accelerate all obligations, increase the interest rate, terminate its commitments, and exercise contractual and legal remedies. Proceeds from the collateral will be applied ratably to Lifeward’s obligations under both the initial and subsequent secured promissory notes.
Lifeward Ltd. is asking shareholders to approve the acquisition of Oratech Pharma from Oramed and a related private placement that will significantly change its ownership and capital structure. Proposal 1 covers issuing approximately 131,297,754 ordinary shares in connection with the Oratech deal and associated warrants and convertible notes.
At closing, Oramed would receive ordinary shares and pre-funded warrants equal to 49.99% of Lifeward’s fully diluted equity, with no more than 45.00% issued as ordinary shares initially. Lifeward also agreed to senior secured convertible notes of $10 million plus an additional $10 million, convertible at $0.45 per share with 8% interest, and related warrants. Oramed is further entitled to a 4% revenue share on ReWalk product net revenue, capped by time, aggregate payments or a $200 million market capitalization trigger.
Shareholders will also vote on adding two external directors tied to the transaction, approving external director compensation, increasing shares under the 2025 incentive plan, granting equity to the CEO, and reappointing the independent auditor. Several proposals require both an ordinary majority and a special majority under Israeli law.
Lifeward Ltd. received an additional 180-day grace period from Nasdaq, until August 3, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company previously failed to meet this rule by the initial February 2, 2026 deadline.
Shareholders have already approved a reverse share split, and the board has set a 1-for-12 split ratio, with timing and implementation to be decided. Lifeward plans to monitor its share price and consider actions, including the approved reverse split, but notes there is no assurance it will regain compliance or avoid a potential delisting process.